---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-008498"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:27:07.352392+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reviva reports FY2022 net loss of $24.3M; cash runway through Q3 2023; Phase 3 topline data expected mid-2023

## Summary
- Net loss of $24.3M ($1.25 per share) vs $8.5M ($0.58 per share) in FY2021.
- Cash and equivalents $18.5M as of Dec 31, 2022, down from $29.7M; cash expected to fund operations through Q3 2023.
- Over 50% of ~400 patients enrolled in pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.
- Completed majority of prelaunch studies for NDA submission; positive drug-drug interaction data reported.
- May initiate Phase 2a studies in bipolar disorder, MDD, ADHD in H2 2023 subject to additional financing.

## SEC filing metadata
- accession: 0001437749-23-008498
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/0001437749-23-008498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/rvph20230327_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-008498
- JSON: https://secwatch.observer/filing/0001437749-23-008498.json
- Plain text: https://secwatch.observer/filing/0001437749-23-008498.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported full year ended December 31, 2022 results: net income approximately $24.3 million, EPS $1.25 per share.
  - Period: full year ended December 31, 2022
  - Net income: approximately $24.3 million
  - EPS: $1.25 per share
  - Result: reported results
  source text: For the year ended December 31, 2022, net loss was approximately $24.3 million, or $1.25 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/0001437749-23-008498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.